Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Predictions

Novozymes A/s Nam. B

Start price
Target price
Perf. (%)
€55.52
€63.00
-2.918%

Market Leader or Top 3
Higher EBIT margin than peer group
positive Cash Flow expected
Revenue decline/stagnation expected
Samsung Sdi GDR

Start price
Target price
Perf. (%)
€77.40
-
0.775%

Future proof or reliable business model
Market Leader or Top 3
Innovative
Well known brand
Satsuma Pharmaceuticals Inc.

Start price
Target price
Perf. (%)
€4.30
€2.00
-19.535%

Probably not worthwhile Investment
Revenue decline/stagnation expected
EBIT decline/stagnation expected
Lower EBIT Margin than peer group
Geely Automobile Holdings

Start price
Target price
Perf. (%)
€1.72
-
-1.749%

Some uniques
Below average Management
Business model of the past or high risk
News Corp. B

Start price
Target price
Perf. (%)
€12.60
-
-4.885%

Low dividend yield expected
Revenue decline/stagnation expected
negative Cash Flow expected
Few uniques
Quantafuel As

Start price
Target price
Perf. (%)
€8.14
-
-30.958%

Could be worthwhile Investment >10% per year
EBIT growth >5% per year expected
Lower EBIT Margin than peer group
High valuation
Curevac N.V.

Start price
Target price
Perf. (%)
€48.40
-
-21.934%

Could be very worthwhile Investment >20% year
Revenue growth >5% per year expected
Higher EBIT margin than peer group
Fair valuation
BioNTech SE ADR

Start price
Target price
Perf. (%)
€52.11
€75.00
10.017%

Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
Future proof or reliable business model
Tesla Inc

Start price
Target price
Perf. (%)
€298.75
-
17.255%

Panasonic Corp.

Start price
Target price
Perf. (%)
€7.65
-
-2.745%

Some uniques
Future proof or reliable business model
Innovative
Differentiated customer and product portfolio
Moderna Inc.

Start price
Target price
Perf. (%)
€48.88
-
22.218%

Significant cyclical dependencies
Higher risks for its business
Jinkosolar ADR

Start price
Target price
Perf. (%)
€17.58
-
74.346%

Sustainability is very important
Innovative
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Shop Apotheke Europe NV

Start price
Target price
Perf. (%)
€135.80
€175.00
6.038%

Could be very worthwhile Investment >20% year
Revenue growth > 30% per year expected
EBIT growth > 30% per year expected
Very positive Cash Flow expected
Beyond Meat Inc

Start price
Target price
Perf. (%)
€108.80
€150.00
22.537%

Could be very worthwhile Investment >20% year
Revenue growth > 30% per year expected
EBIT growth > 30% per year expected
High valuation
Borussia Dortmund

Start price
Target price
Perf. (%)
€5.69
-
-2.461%

Top 10 in its market
Capable Management
Some uniques
Revenue decline/stagnation expected
Carnival plc

Start price
Target price
Perf. (%)
€12.60
-
-16.032%

Could be worthwhile Investment >10% per year
Future proof or reliable business model
Higher risks for its business
Significant cyclical dependencies
Southwest Airlines Co.

Start price
Target price
Perf. (%)
€33.18
-
-3.843%

Could be worthwhile Investment >10% per year
Capable Management
Growths faster than the competition
Higher risks for its business
Infineon Technologies AG

Start price
Target price
Perf. (%)
€23.01
-
0.152%

Could be worthwhile Investment >10% per year
Trillium Therapeutics

Start price
Target price
Perf. (%)
€8.28
-
41.908%

Could be very worthwhile Investment >20% year
LPKF Laser & Electronics AG

Start price
Target price
Perf. (%)
€21.00
€25.00
-2.143%

Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Higher EBIT margin than peer group
NVIDIA Corp.

Start price
Target price
Perf. (%)
€420.00
€470.00
5.500%

Could be very worthwhile Investment >20% year
Revenue growth > 30% per year expected
EBIT growth > 30% per year expected
Higher EBIT margin than peer group
Zooplus AG

Start price
Target price
Perf. (%)
€140.40
€150.00
7.407%

Probably not worthwhile Investment
Shop Apotheke Europe NV

Start price
Target price
Perf. (%)
€126.00
€155.00
14.286%

Medium risks for its business
Eli Lilly Corp.

Start price
Target price
Perf. (%)
€128.00
€135.00
0.969%

Could be worthwhile Investment >10% per year
Future proof or reliable business model
Higher risks for its business
Curevac N.V.

Start price
Target price
Perf. (%)
€52.00
-
-27.346%